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University of Ljubljana, Ljubljana, Slovenia and 3) Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, SloveniaAbstractAfter a primary infection, human cytomegalovirus (HCMV) remains latent in certain human cells. Different stimuli, including immune
deﬁciency and severe infection, can trigger the reactivation of latent HCMV infection. In the last decade, the role of the reactivation in
immunocompetent patients with serious illness has been intensely studied; however, the knowledge of the potential role of moderately
severe infections on HCMV dynamics is limited. In the prospective study, 80 HCMV-seropositive, immunocompetent adult patients with
community-acquired pneumonia (CAP), treated outside the intensive care unit (ICU), were monitored with real-time polymerase chain
reaction (PCR) for the presence of HCMV DNA. Detection of HCMV DNA in whole blood and/or plasma was interpreted as
reactivation of latent HCMV infection. HCMV DNA was detected in 6 of 80 (7.5%) patients. All HCMV DNA–positive patients were
classiﬁed according to the pneumonia severity index (PSI) as high-risk classes IV or V; thus, HCMV DNAaemia rate within these two PSI
classes was 16.7%. All of the patients had positive whole blood samples, whereas plasma samples were positive in a single patient. We
did not detect any signiﬁcant differences comparing six patients with proven HCMV DNAaemia and 74 patients in whom HCMV
DNAaemia was not demonstrated regarding the levels of inﬂammatory parameters on admission, length of treatment with supplemental
oxygen, and length of hospital stay. In conclusion, the ﬁnding of HCMV DNAaemia in patients with CAP treated outside the ICU is a
rare event and occurs only in patients with PSI classes designating more severe pneumonia.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: rajko.saletinger@ukc-mb.siIntroductionHuman cytomegalovirus (HCMV) is the member of a Beta-
herpesvirinae subfamily [1]. Infection with the virus in humans is
ubiquitous, with seroprevalence rates in adults between 60%
and 100% [2]. After a primary infection, HCMV establishes aClinical Microbiology and Infection © 2014 European Society of Clatent infection in certain human cells. Different stimuli, including
immunosuppression and inﬂammation, can trigger the reac-
tivation of latent HCMV infection [3]. For a long time HCMV has
been recognized as one of the most important pathogens in
immunocompromised patients, such as solid organ transplant
recipients, patients with haematological malignancies, and HIV
patients. In the last decade the role of serious infections in
activation of latent HCMV infection in immunocompetent pa-
tients also is being scrutinised. The studies comprised critically ill
patients treated at intensive care units (ICU) [4-10].
The aim of our study was to determine the rate of HCMV
DNAaemia in immunocompetent patients with community-
acquired pneumonia (CAP) treated outside the ICU, toClin Microbiol Infect 2015; 21: 97–102
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.09.001
98 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIidentify factors associated with the presence of HCMV
DNAaemia, and to assess its effect on the clinical course of
CAP. To the best of our knowledge, this is the ﬁrst study on
HCMV dynamics in patients with CAP treated outside the ICU.
Materials and methodsPatients
This prospective study was conducted at the Department of In-
fectious Diseases of the University Medical Centre Maribor,
Slovenia, between July 2011 and December 2013. The inclusion
criteria were the presence of CAP in an adult patient without a
known immunodeﬁciency, who provided an informed consent.
The diagnosis of CAP was made according to the criteria of the
British Thoracic Society [11]. Exclusion criteria were: age younger
than 18 years, pregnancy, HCMV seronegativity, known tubercu-
losis, hospitalisation in the last 10days before admission, treatment
with certain antiviral drugs within the last week (cidofovir, fos-
carnet, ganciclovir, valganciclovir, acyclovir, valacyclovir), known
congenital or acquired immune defects (HIV infection, immuno-
suppressive therapy within the last month, known haematologic
malignancies or metastatic carcinoma), absolute neutrophil count
below 500/μL on admission or during follow-up, and blood
transfusion within the last month and during study performance.
Study protocol
The study was approved by Slovenian National Medical Ethics
Committee (No. 110/01/11). Informed consent was provided by
all patients included in the study. Patients who fulﬁlled inclusion
criteria and did not have any exclusion criteriawere tested for the
presence of anti-HCMV antibodies within 24 hours. The pres-
ence of IgG anti-HCMVwas determined with the LIAISONCMV
IgG II assay (DiaSorin S.P.A., Saluggia, Italy), following the manu-
facturer’s instructions. Patients with positive anti-HCMV IgG
were screened for the presence of HCMV DNA on days 1, 5, 10
and 20 using commercial real-time polymerase chain reaction
(PCR)–based assay. According to the manufacturer’s data, the
limit of detection 95% is 22 copies/PCR reaction or 555 copies/
mL, and limit of detection 5% 1 copy/PCR reaction or 30 copies/
mL. HCMV DNA load was measured in each patient in both
plasma and whole blood. Total DNA was extracted from 200 μL
of whole blood and 200 μL of plasma samples using MagNA Pure
Compact Nucleic Acid Isolation Kit I (Roche Diagnostics, Pleas-
anton, CA, USA) on MagNA Pure Compact Instrument (Roche
Diagnostics), and HCMV viral load was subsequently determined
using CMV R-gene kit (Argene, Verniolle, France), following
manufacturer’s instructions. The presence of measurable HCMV
DNA in either whole blood or plasma sample was interpreted to
represent the reactivation of latent HCMV infection.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectAt admission chest radiograph and the arterial blood gas
analysis were performed, and the severity of pneumonia was
assessed according to the pneumonia severity index (PSI). The
patient’s inﬂammatory parameters (white blood cell count
[WBC] and differential, C-reactive protein [CRP] and pro-
calcitonin concentrations, erythrocyte sedimentation rate),
basic kidney and liver function tests, and concentration of
electrolytes were determined on days 1, 3, 5, 7, 10 and 20. The
regression of lung inﬁltrates was followed up using chest
radiograph during the hospital stay and according to the pa-
tient’s clinical condition also during follow-up after discharge
from the hospital. The ﬁrst chest radiograph was performed on
admission and the second on day 7 in the majority of patients.
On admission, two pairs of blood cultures were obtained
from each patient. Analysis of blood cultures was performed at
a microbiological laboratory with the automatic system BacT
ALERT 3D. Pretreatment Gram stain and culture of sputum
were attained according to standard procedures. Sputum
samples were cultured only if they fulﬁlled quality criteria: 25 or
more neutrophils and 10 or fewer squamous epithelial cells per
low-power ﬁeld. In the vast majority of patients, tests for the
detection of urinary antigens of Streptococcus pneumoniae and
Legionella pneumophila were performed. Urinary antigen of
S. pneumoniae was determined with rapid immunochromato-
graphic assay BinaxNOW (Alere Scarborough Inc., Scar-
borough, ME, USA). For the detection of urinary antigen of
L. pneumophila, Legionella urine antigen Enzyme-Immunoassay
(Bio-Rad, Marnes-la-Coquette, France) was used.
Patients included in the study were clinically followed up on a
regular basis. During the hospital stay, they were checked and had
their vital signs (temperature, blood pressure, heart rate, respi-
ratory rate, and pulse oximetry)measured at least twice daily. The
decision for the empirical antimicrobial treatment on admission
was made by the attending physician or physician on duty. In pa-
tients with an established aetiology of CAP, antimicrobial treat-
ment was directed by the results of microbiological studies.
Statistics
Data were analysed using the statistical package SPSS (version
20). Numerical data were analysed with the Mann-Whitney
U test. Fisher’s exact test was performed to compare cate-
gorical variables. A value of p <0.05 was considered statistically
signiﬁcant.ResultsStudy population
Of 192 patients with CAP admitted to our department during
the study period (July 2011 to December 2013), 117 met theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 97–102
CMI Saletinger et al. HCMV DNAaemia in patients with CAP 99eligibility criteria and were tested for the presence of IgG anti-
HCMV. Of 96 patients who were anti-HCMV seropositive, 80
(83.3%) ﬁnished the study according to the protocol. The de-
tails are presented in the ﬂowchart (Fig. 1).
In all patients meeting the eligibility criteria, the severity of
pneumonia was determined on admission using PSI. A group of
80 patients who ﬁnished the study according to the protocol
did not differ signiﬁcantly according to the PSI from the group
of 16 patients who were excluded from the study (p 0.47).
Among 80 patients who fulﬁlled the study protocol re-
quirements, 44 (55%) were men. Seven (8.8%) patients were
nursing home residents. The youngest patient was 18 years old,
and the oldest was 99 years old (median 63.5 years). Patients
were admitted to the hospital 4 (1 to 15) days after the onset of
symptoms. Twenty patients (25%) were active smokers; 75% of
them were men. Eight (10%) patients admit excessive alcohol
consumption (87.5% of them also were men).
Severity of pneumonia according to PSI
According to the PSI scoring system, 44 (55%) patients were
classiﬁed to low-risk classes I to III; they were admitted to the
hospital because of respiratory insufﬁciency and the need forFIG. 1. Flowchart of the study. CAP, community acquired pneumonia;
HCMV, human cytomegalovirus.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyoxygen supplement or very elevated inﬂammatory parameters
(WBC >20 × 109/L, CRP >250 mg/L). Thirty-six (45%) patients
were stratiﬁed according to PSI to classes IV and V with the
highest risk of death.
Aetiology of CAP
The aetiology of CAP was established in 36 of 80 (45%) pa-
tients. Blood cultures were positive in 15 of 80 (18.8%) pa-
tients: S. pneumoniae in 10 (12.5%) patients, Escherichia coli in 4
(5%) patients and Staphylococcus aureus in 1 patient.
Only 32 of 80 (40%) patients had a productive cough on
admission and were able to give the sputum sample, whereas in
other patients cough was dry or absent. Sputum was obtained
in 28 (35%) patients. Fifteen of 28 (53.6%) sputum samples
fulﬁlled quality criteria and were cultured according to the
standard protocol. Five of them were positive: from two
samples S. aureus was isolated, whereas another three samples
showed the growth of S. pneumoniae, Klebsiella pneumoniae and
Moraxella catarrhalis, respectively.
Urinary antigen of S. pneumoniae tested positive in 11 of 79
(13.9%) samples—4 urine-positive patients also had positive
blood cultures for S. pneumoniae. The presence of urinary an-
tigen of L. pneumophila was established in 10 of 78 (12.8%)
samples.
HCMV DNA detection
HCMV DNA in either whole blood or plasma was detected in 6
(7.5%) of 80 patients; 3 men and 3 women. Patients with
established HCMV DNAaemia were older than the rest of the
group (median 79 years; range 63 to 82 years vs. median 62
years; range 18 to 99 years), however the difference was not
found signiﬁcant (p 0.075). In all 6 patients HCMV DNA was
detected in whole blood samples, whereas in 1 patient it was
also demonstrated in plasma. This patient was the only one with
high and sustained HCMV DNAaemia. He was 81 years old,
male, with bilateral lung inﬁltrates on admission and his blood
cultures were positive for S. aureus. Basic characteristics of
patients with HCMV DNAaemia, interpreted as having reac-
tivation of latent HCMV infection, are presented in Tables 1
and 2.
A comparison of patients with and without HCMV DNA in
blood is shown in Table 3. Patients with proven HCMV
DNAaemia had higher points determined according to the PSI
classiﬁcation (p 0.009) and more frequently belonged to PSI risk
groups IV and V (p 0.006). We also found signiﬁcantly lower
absolute lymphocyte count at day 7 in this group of patients.
They had also higher CRP and procalcitonin levels at admission,
needed longer supplementary therapy with oxygen, had longer
hospital stay, and had more often positive blood cultures;
however, these differences were not statistically signiﬁcant.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 97–102
TABLE 1. Characteristics of patients with proven HCMV DNA in whole blood and/or plasma
Sex Female Female Female Male Male Male
Age (y) 82 71 80 78 81 63
Comorbidity, smoking, alcohol
consumption
CV disease, CHF Smoking None CHF Liver disease, CV disease,
smoking, excessive
alcohol consumption
Liver disease, excessive
alcohol consumption
WBC1 (×10
9/L) 11.66 17.47 22.66 17.18 15.10 7.00
WBCR (×10
9/L) 9.27 8.67 10.83 5.77 15.10 5.07
CRP1 (mg/L) 162 374 333 96 279 375
CRPR (mg/L) 53 43 65 3 279 15
PCT1 (ng/L) 10.52 5.7 39.65 0.33 0.32 1.9
PCTR (ng/L) ND 0.17 0.52 0.06 0.32 0.11
Day of HCMV DNAaemia detection 20 10 10 20 1, 5, 10, 20 20
Time from onset of symptoms to
HCMV DNA detection (d)
23 25 13 25 7 23
VL (copies/mL) 284 174 976 750 7,480–12,500 786
Aetiology of CAP E. coli* ND ND ND S. aureus* S. pneumoniae*
PSI class 5 4 4 4 5 5
Duration of WBC > 10 × 109/mL
(d)
4 1 10 21 18 0
Duration of CRP > 50 mg/L (d) 6 8 10 10 18 9
Duration of PCT > 0.5 ng/L (d) 9 5 9 0 0 5
Duration of temperature >37.6°C (d) 2 3 1 2 2 7
Need for supplemental oxygen
treatment (d)
7 7 0 0 7 5
Hospital stay (d) 15 14 10 8 23 9
HCMV, human cytomegalovirus; CV, cerebrovascular; CHF, congestive heart failure; WBC1, white blood cell count level on admission; WBCR, white blood cell count level at the
time of HCMV DNA detection; CRP1, C-reactive protein level on admission; CRPR, C-reactive protein level at the time of HCMV DNA detection; PCT1, procalcitonin level on
admission; PCTR, procalcitonin level at the time of HCMV DNA detection; ND, not determined; VL, viral load in the whole blood sample; CAP, community acquired pneumonia PSI,
pneumonia severity index.
*Isolates from blood cultures.
100 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIDiscussionAmple data exist on the reactivation of HCMV in severely
immunodeﬁcient patients, but the corresponding information
for immunocompetent hosts is much less comprehensive and is
nearly exclusively limited to the critically ill patients managed in
the ICUs. To the best of our knowledge, there is no study on
HCMV dynamics in patients with CAP treated outside the ICU
published in peer-reviewed literature. As shown in Table 4, the
published studies differed according to the number of included
patients and their diagnoses, the approaches used for the
assessment of the presence of HCMV (recognition of anti-
genemia, detection of HCMV DNA by PCR or real-time PCR)
and their sensitivity, examined specimens (plasma, leukocytes,
whole blood, bronchial/tracheal secretion), and duration of
illness prior to obtaining the specimens. This heterogeneity
makes interpretation of the distinct proportions of patients
with HCMV presence found in these studies (from 8.3% toTABLE 2. Characteristics of patient with persistent HCMV
DNAaemia
Parameter Day 1 Day 5 Day 10 Day 20
VLWB (copies/mL) 7480 6080 12 500 7800
VLP (copies/mL) Negative 2600 3800 1480
WBC (×109/L) 15.10 14.83 11.12 7.35
CRP (mg/L) 279 141 80 25
PCT (ng/L) 0.32 0.19 0.08 0.08
HCMV, human cytomegalovirus; VLWB, viral load in whole blood sample; VLP, viral
load in plasma sample; WBC, white blood cell count; CRP, C-reactive protein level;
PCT, procalcitonin level.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect55.2%) difﬁcult. In four studies in which identical approaches for
detection of HCMV (real-time PCR) were used for equivalent
specimens as in our study, HCMV DNA was demonstrated in
8.3% to 33% of patients in plasma and in 55.2% of patients in
blood [5, 7, 10, 12]. Even comparison of these results may be
biased by distinct sensitivities (and speciﬁcities) of the assays
used in individual study.
In the present prospective study, comprising patients with
CAP who— in contrast to previous reports—did not need
treatment in the ICU, HCMV DNA was detected in whole
blood specimens of only 6 of 80 (7.5%) patients and in plasma
samples of the single (1.3%) patient. The low proportion in
comparison to previous reports is probably related to less se-
vere disease in our patients. The importance of the severity of
illness also was shown in the present study, in which HCMV
DNA was demonstrated in 6 of 36 (16.7%) patients who were
classiﬁed according to the PSI to risk class IV and V but in 0 of
44 patients with low PSI risk classes I to III (p 0.006).
In the present study, the detection of HCMV genome in
whole blood/plasma was interpreted as reactivation of HCMV
infection. The detection rate depends upon the sensitivity of a
diagnostic approach. In our study we used a HCMV DNA test
with a clinically validated cut-off. Although a test with a higher
analytical sensitivity would most probably produce more
HCMV DNA–positive results in samples containing minute
quantities of HCMV, the clinical signiﬁcance of such ﬁndings
would be difﬁcult to interpret.
The present study corroborates previous ﬁndings that
whole blood is a more appropriate specimen than plasma forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 97–102
TABLE 3. Characteristics of patients with and those without HCMV DNA in whole blood and/or plasma
Characteristic, parameter
HCMV DNA
negative (n [ 74)
HCMV DNA
positive (n [ 6) OR (95% CI) p
PSI points 79.5 (22–202) 121 (101–211) NA 0.009
Risk classes: IN 0.006
I– III 44 (59.5%) 0
IV–V 30 (40.5%) 6 (100%)
WBC1 (×10
9/L) 12.34 (2.35–33.92) 16.14 (7.00–22.66) NA 0.36
CRP1 (mg/L) 188 (6–589) 306 (96–375) NA 0.16
PCT1 (ng/L) 1.16 (0.06–100) 8.11 (0.33–39.65) NA 0.36
ALC7 (×10
9/L) 1.82 (0.29–3.94) 1.31 (0.98–1.91) NA 0.053
Positive blood culture result 12 (16.2%) 3 (50%) 5.17 (0.93–28.73) 0.08
Aetiology of CAP established 32 (43.2%) 3 (50%) 1.31 (0.25–6.94) 1.00
Supplemental oxygen
No. of patients 36 (48.6%) 4 (66.7%) 2.11 (0.36–12.24) 0.68
No. of days 4.5 (1–21) 7 (5–7) NA 0.29
LOS (d) 10 (4–36) 12 (8–23) NA 0.19
Note: data are median (range) values or %
HCMV, human cytomegalovirus; PSI, pneumonia severity index; NA, not applicable; IN, inﬁnity; WBC1, white blood cell count level on admission; CRP1, C-reactive protein level on
admission; PCT1, procalcitonin level on admission; ALC7, absolute lymphocyte count on day 7; CAP, community acquired pneumonia; LOS, length of hospital stay.
CMI Saletinger et al. HCMV DNAaemia in patients with CAP 101demonstration of minute quantities of HCMV DNA because
whole blood usually yields higher HCMV DNA loads [13, 14]. In
all but one of our patients HCMV DNA was detected only in
whole blood, whereas plasma samples remained negative. In
ﬁve of six patients the levels of detected HCMV DNAaemia
were low (<1000 copies/mL) whereas one patient developed
high levels of HCMV DNAaemia with peak of 12 500 copies/mL
at day 10. This particular patient was the only one in whom
HCMV DNA was detected not only in whole blood (in 4 of 4
samples) but also in plasma (in 3 of 4 samples). However, levels
of detected HCMV DNAaemia were signiﬁcantly higher in his
whole blood samples (Table 2).
Some studies indicate that not only whole blood but also
some other sources yield higher HCMV DNA loads than
plasma. Chilet et al., who identiﬁed higher detection rates of
HCMV DNA in bronchoalveolar lavage ﬂuid than in plasma,
concluded that monitoring for the presence of HCMV only inTABLE 4. Published studies on HCMV reactivation in patients who
Study [reference] Inclusion criteria No. of patients
Diagnost
(specime
Von Müller et al. [4] Septic shock, ICU stay >7 d 23 Antigenem
Limaye et al. [5] Critically ill 120 Real-time
Chiche et al. [6] Mechanically ventilated
patients >2 d
242 Antigenem
Chilet et al. [7] ICU stay >5 d 53 Real-time
(plasma
Heininger et al. [8] Critically ill patients with
severe sepsis
86 PCR
(leukoc
trachea
Ziemann et al. [9] ICU stay >14 d 99 PCR (plas
Bordes et al. [10] Total burn surface area >15% 29 Real-time
(whole
Nunez et al.* [12] Acute heart failure 129 Real-time
(plasma
HCMV, human cytomegalovirus; ICU, intensive care unit; ND, not determined; PCR, polym
*From each patient specimens were obtained only on one occasion within the ﬁrst 5 days of a
care unit.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologythe blood compartment may underestimate the actual inci-
dence of HCMV infection (‘reactivation’) in critically ill patients
[7]. The ﬁndings were corroborated with the study by Hei-
ninger et al., who also found HCMV DNA more frequently in
tracheal aspirates than in plasma samples (37.1% vs. 11.6%) [8].
Although we enrolled 80 patients with CAP, the low HCMV
DNAaemia rate precluded robust statistical analysis of its po-
tential effect on the course and outcome of the CAP and
identiﬁcation of factors associated with HCMV DNAaemia. As
stated earlier, all of our patients with proven HCMV DNAaemia
belonged to the PSI risk class IV and V. The ﬁnding suggests that
scores obtained by PSI are associated with prediction of HCMV
DNAaemia. This is in contrast to the results of the meta-
analysis, in which severity scores obtained by three scoring
systems (including Acute Physiology and Chronic Health Eval-
uation [APACHE] II, sepsis-related organ failure assessment
[SOFA] score, and simpliﬁed acute physiologic score [SAPS] II)were not immunocompromised before the current illness
ic approach
n)
Rate of detected
reactivation (%)
Duration of illness
(d) to positivity
reported as median
(range) or mean ± SD
ia 30.4 7 (0–14)
PCR (plasma) 33 12 (3–57)
ia 13.6 17 (7–26)
PCR
, tracheal aspirate)
39.7
Plasma 29
Tracheal aspirate 42
12 (0–34)
plasma 16.5 (0–28)
Tracheal aspirate 11 (0–34)
ytes, plasma,
l secretion)
40.7
Tracheal secretion 32.5
Leukocytes 25.6
Plasma 11.6
Tracheal secretion 14 (0–77)
Blood 24.5 (0–49)
ma) 35 17 ± 15.3
PCR
blood)
55.2 13 ± 9
PCR
)
8.3 ND
erase chain reaction.
dmission to hospital; this was the only study assessing patients outside of the intensive
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 97–102
102 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIdid not correlate with the risk of HCMV infection deﬁned as the
evidence of antigenemia, DNAaemia, and/or positive viral cul-
tures from blood or other clinical specimens [15].
Although in the group of our patients with established
HCMV DNAaemia the levels of inﬂammatory parameters on
admission as well as the proportion of patients with positive
blood culture results were higher than in the group with
negative real-time PCR ﬁndings, and the length of hospital stay
and duration of treatment with supplemental oxygen were
longer, the differences were not signiﬁcant. Because of the
relatively small number of patients with proven HCMV
DNAaemia, all of these data should be interpreted with caution.
Our ﬁndings do not enable distinction between the possibilities
that the presence of the HCMV genome is a marker of severity
of underlying illness, is a concomitant intensiﬁer of the illness,
or is associated with both.
In conclusion, the ﬁrst study on the presence of HCMV
DNA in patients with CAP treated outside the ICU showed
that the presence of HCMV DNAaemia in blood, interpreted as
reactivation of latent HCMV infection, occurs not only in crit-
ically ill patients hospitalized in the ICU but also in patients with
CAP treated outside the ICU. However, the HCMV DNAaemia
is a rare event occurring predominantly in older patients with
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